mefloquine (lariam) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Mefloquine, sold under the brand names Lariam among others, is a medication used to for the treatment of mild to moderate acute malaria caused by Mefloquineuine-susceptible strains of Plasmodium falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax. Also for the prophylaxis of Plasmodium falciparum and Plasmodium vivax malaria infections, including prophylaxis of chloroquine-resistant strains of Plasmodium falciparum. Mefloquine acts as a blood schizonticide. Mefloquine is active against the erythrocytic stages of Plasmodium species. However, the drug has no effect against the exoerythrocytic (hepatic) stages of the parasite. Mefloquine is effective against malaria parasites resistant to chloroquine. Mefloquine is a chiral molecule. According to some research, the (+) enantiomer is more effective in treating malaria, and the (-) enantiomer specifically binds to adenosine receptors in the central nervous system, which may explain some of its psychotropic effects.   NCATS

Chemistry

  • SMILES: OC(C1CCCCN1)c2cc(nc3c(cccc23)C(F)(F)F)C(F)(F)F
  • InChIKey: XEEQGYMUWCZPDN-UHFFFAOYSA-N
  • Mol. Mass: 378.32
  • ALogP: 4.45
  • ChEMBL Molecules:
    mefloquine  
    mefloquine hydrochloride  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$4.0874
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol | benzenesulfonamide, 4-amino-n-(5,6-dimethoxy-4-pyrimidinyl)-, mixt. with 5-(4-chlorophenyl)-6-ethyl-2,4-pyrimidinediamine and (r*,s*)-(+-)-alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol monohydrochloride | fansimef | gnf-pf-5544 | lariam | mefaquin | mefloquin | mefloquina | mefloquine | (+/-)-mefloquine | (+)-mefloquine | méfloquine | mefloquine hcl | mefloquine hydrochloride | mefloquine-sulfadoxine-pyrimethamine | mefloquinum | mephaquin | mephloquine | mephloquine hcl | mephloquine hydrochloride | msp 4 | ro-215998 | ro-215998001 | [(r*,s*)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol | wr-142490

Organizations (99)

Research & Development (94)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (21)

Approved Indications (1)


 

Malaria (approved 1989)

Experimental Indications - Clinical Trial Phases 1-4 (21)


 

Alzheimer Disease (Phase 1)

Anemia, Sickle Cell (Phase 1/Phase 2)

Cognitive Dysfunction (Phase 1)

COVID-19 (Phase 2/Phase 3)

Glioblastoma (Phase 1)

Gliosarcoma (Phase 1)

Healthy Volunteers (Phase 4)

HIV Infections (Phase 3)

Leukoencephalopathy, Progressive Multifocal (Phase 1/Phase 2)

Malaria (Phase 4)

Malaria, Falciparum (Phase 4)

Malaria, Vivax (Phase 4)

Parasitic Diseases (Phase 4)

Plasmodium falciparum (Phase 3)

Pneumonia, Viral (Phase 2)

Pregnancy (Phase 2/Phase 3)

Pregnancy Complications (Phase 3)

Respiratory Insufficiency (Phase 2)

Schistosoma haematobium (Phase 3)

Schistosoma mansoni (Phase 3)

Schistosomiasis haematobia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 54
  • # of Trial Organizations: 94

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue